AAPL   383.70 (+0.61%)
MSFT   215.62 (+1.31%)
FB   245.07 (+0.61%)
GOOGL   1,524.05 (+1.36%)
NVDA   417.23 (+2.10%)
CGC   16.18 (-0.92%)
BABA   261.82 (+1.61%)
MU   49.56 (-0.30%)
GE   6.73 (-1.89%)
TSLA   1,388.89 (+1.68%)
AMD   54.36 (+1.74%)
T   29.66 (-2.63%)
ACB   11.94 (-1.81%)
F   5.99 (-1.64%)
GILD   75.35 (-0.34%)
DIS   117.00 (+0.29%)
BAC   22.72 (-1.69%)
NFLX   505.98 (+0.64%)
BA   176.82 (-1.81%)
AAPL   383.70 (+0.61%)
MSFT   215.62 (+1.31%)
FB   245.07 (+0.61%)
GOOGL   1,524.05 (+1.36%)
NVDA   417.23 (+2.10%)
CGC   16.18 (-0.92%)
BABA   261.82 (+1.61%)
MU   49.56 (-0.30%)
GE   6.73 (-1.89%)
TSLA   1,388.89 (+1.68%)
AMD   54.36 (+1.74%)
T   29.66 (-2.63%)
ACB   11.94 (-1.81%)
F   5.99 (-1.64%)
GILD   75.35 (-0.34%)
DIS   117.00 (+0.29%)
BAC   22.72 (-1.69%)
NFLX   505.98 (+0.64%)
BA   176.82 (-1.81%)
AAPL   383.70 (+0.61%)
MSFT   215.62 (+1.31%)
FB   245.07 (+0.61%)
GOOGL   1,524.05 (+1.36%)
NVDA   417.23 (+2.10%)
CGC   16.18 (-0.92%)
BABA   261.82 (+1.61%)
MU   49.56 (-0.30%)
GE   6.73 (-1.89%)
TSLA   1,388.89 (+1.68%)
AMD   54.36 (+1.74%)
T   29.66 (-2.63%)
ACB   11.94 (-1.81%)
F   5.99 (-1.64%)
GILD   75.35 (-0.34%)
DIS   117.00 (+0.29%)
BAC   22.72 (-1.69%)
NFLX   505.98 (+0.64%)
BA   176.82 (-1.81%)
AAPL   383.70 (+0.61%)
MSFT   215.62 (+1.31%)
FB   245.07 (+0.61%)
GOOGL   1,524.05 (+1.36%)
NVDA   417.23 (+2.10%)
CGC   16.18 (-0.92%)
BABA   261.82 (+1.61%)
MU   49.56 (-0.30%)
GE   6.73 (-1.89%)
TSLA   1,388.89 (+1.68%)
AMD   54.36 (+1.74%)
T   29.66 (-2.63%)
ACB   11.94 (-1.81%)
F   5.99 (-1.64%)
GILD   75.35 (-0.34%)
DIS   117.00 (+0.29%)
BAC   22.72 (-1.69%)
NFLX   505.98 (+0.64%)
BA   176.82 (-1.81%)
Log in

NASDAQ:PSTIPluristem Therapeutics Stock Price, Forecast & News

$8.87
-0.03 (-0.34 %)
(As of 07/9/2020 10:02 AM ET)
Add
Compare
Today's Range
$8.83
Now: $8.87
$9.01
50-Day Range
$7.05
MA: $8.14
$9.11
52-Week Range
$2.82
Now: $8.87
$13.29
Volume1,642 shs
Average Volume491,790 shs
Market Capitalization$220.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.6
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Read More
Pluristem Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.01 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50,000.00
Book Value$1.43 per share

Profitability

Net Income$-35,310,000.00

Miscellaneous

Employees172
Market Cap$220.95 million
Next Earnings DateN/A
OptionableOptionable

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

How has Pluristem Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSTI stock has increased by 206.9% and is now trading at $8.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pluristem Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pluristem Therapeutics.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.10. View Pluristem Therapeutics' earnings history.

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Pluristem Therapeutics's stock reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PSTI?

5 equities research analysts have issued 12 month price targets for Pluristem Therapeutics' shares. Their forecasts range from $12.00 to $15.50. On average, they expect Pluristem Therapeutics' share price to reach $12.88 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View analysts' price targets for Pluristem Therapeutics.

Has Pluristem Therapeutics been receiving favorable news coverage?

News articles about PSTI stock have trended negative on Thursday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pluristem Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Pluristem Therapeutics.

Who are some of Pluristem Therapeutics' key competitors?

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Protalix Biotherapeutics (PLX), NVIDIA (NVDA), Novavax (NVAX), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD) and Pfizer (PFE).

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the following people:
  • Mr. Zami Aberman, Chairman & Co-CEO (Age 65)
  • Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 48)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 35)
  • Mr. Boaz Leshem, VP Operations & Manufacturing (Age 59)
  • Ms. Efrat Kaduri, Director of Bus., Investor and PR

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $8.87.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $220.95 million and generates $50,000.00 in revenue each year. Pluristem Therapeutics employs 172 workers across the globe.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is www.pluristem.com.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972-74-710-8600 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.